

Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study

Mikhail Kosiborod, MD, Carolyn S.P. Lam, MBBS PhD, Shun Kohsaka, MD, Dae Jung Kim, MD, Avraham Karasik, MD, Jonathan Shaw, MD, Navdeep Tangri, MD PhD, Su-Yen Goh, MD, Marcus Thuresson, PhD, Hungta Chen, PhD, Filip Surmont, MD, Niklas Hammar, PhD, Peter Fenici, MD

PII: S0735-1097(18)33528-9

DOI: [10.1016/j.jacc.2018.03.009](https://doi.org/10.1016/j.jacc.2018.03.009)

Reference: JAC 24748

To appear in: *Journal of the American College of Cardiology*

Received Date: 5 March 2018

Accepted Date: 5 March 2018

Please cite this article as: Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh S-Y, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P, on behalf of the CVD-REAL Investigators and Study Group, Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study, *Journal of the American College of Cardiology* (2018), doi: 10.1016/j.jacc.2018.03.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study

Mikhail Kosiborod MD<sup>a</sup>, Carolyn S P Lam MBBS PhD<sup>b</sup>, Shun Kohsaka MD<sup>c</sup>, Dae Jung Kim MD<sup>d</sup>, Avraham Karasik MD<sup>e</sup>, Jonathan Shaw MD<sup>f</sup>, Navdeep Tangri MD PhD<sup>g</sup>, Su-Yen Goh MD<sup>h</sup>, Marcus Thuresson PhD<sup>i</sup>, Hungta Chen PhD<sup>j</sup>, Filip Surmont MD<sup>k</sup>, Niklas Hammar PhD<sup>l,m</sup>, Peter Fenici MD<sup>n</sup> on behalf of the CVD-REAL Investigators and Study Group.

<sup>a</sup>Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri; <sup>b</sup>National Heart Centre, Singapore and SingHealth Duke-NUS, Singapore; and University Medical Centre Groningen, the Netherlands; <sup>c</sup>Keio University School of Medicine, Tokyo, Japan; <sup>d</sup>Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea; <sup>e</sup>Tel Aviv University, and Maccabi Healthcare Israel; <sup>f</sup>Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia; <sup>g</sup>Department of Medicine, University of Manitoba, Winnipeg MB, Canada; <sup>h</sup>Singapore General Hospital, Singapore; <sup>i</sup>Statisticon AB, Uppsala, Sweden; <sup>j</sup>AstraZeneca, Gaithersburg, Maryland; <sup>k</sup>AstraZeneca, Luton, United Kingdom; <sup>l</sup>Karolinska Institutet, Stockholm, Sweden; <sup>m</sup>AstraZeneca, Gothenburg, Sweden; <sup>n</sup>AstraZeneca, Cambridge, United Kingdom

**Funding:** This study was funded by AstraZeneca

**Disclosures:** MK: research grants from AstraZeneca and Boehringer Ingelheim, advisory boards for AstraZeneca, Boehringer Ingelheim, Sanofi, Glytec, Novo Nordisk, ZS Pharma, Janssen, Merck (Diabetes) and Novartis; consultant for AstraZeneca, Boehringer Ingelheim, Sanofi, GSK, Janssen, Intarcia, Merck (Diabetes), Novo Nordisk, Glytec and ZS Pharma. CSPL: has received research support from Boston Scientific, Bayer, Thermofisher, Medtronic, and Vifor Pharma; and has consulted for Bayer, Novartis, Takeda, Merck, AstraZeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Roche, and Amgen; SK: has received grants from Bayer Yakuhin and Daiichi Sankyo and consulting fees from Bayer Yakuhin, Bristol-Myers Squibb, and Pfizer.; DJK: has received grant support from LG Life Sciences, Chong Kun Dang and AstraZeneca; has been a consultant for AstraZeneca, Novo Nordisk, and Sanofi; has received speaker fees from Novo Nordisk, Takeda, Handok, CJ Healthcare, Chong Kun Dang, MSD, Hanmi, and AstraZeneca.; AK: has received grants and consulting fees from AstraZeneca, Novo Nordisk, Merck, and Boehringer Ingelheim.; JS: has received honoraria for advisory boards and lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mylan, Novartis, Novo Nordisk, and Sanofi.; NT: has received consulting fees from Otsuka, Tricida, and AstraZeneca. He has received research support from AstraZeneca, including for this work. His research program is supported by the Canadian Institute for Health Research and Research Manitoba; SYG: has received institutional grants from AstraZeneca, Medtronic, and Sanofi. He has participated in advisory boards for Amgen, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Medtronic and Sanofi and has received honoraria for participation; MT: Employee at Statisticon for which AstraZeneca is a client; HC, FS, NH and PF: AstraZeneca employees.

**Acknowledgements:** The authors acknowledge Kevin Kennedy (Saint Luke's Mid America) for his independent validation of the data. Editorial support was provided by Nicola Truss, PhD, inScience Communications, Springer Healthcare, and funded by AstraZeneca.

### Address for correspondence:

Mikhail Kosiborod, MD  
Saint Luke's Mid America Heart Institute

Download English Version:

<https://daneshyari.com/en/article/8666010>

Download Persian Version:

<https://daneshyari.com/article/8666010>

[Daneshyari.com](https://daneshyari.com)